Bayer, DE000BAY0017

Bayer stock sees divided analyst outlook after second quarter results

Published on 08/13/2026 at 11:13 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS

Bayer stock is trading below its recent highs as analysts split between cautious and optimistic targets following the group’s latest second quarter figures and chart levels around the mid-50 euro range.

Extremmakroaufnahme einer weißen Tablette, in zwei Hälften gebrochen; die körnig-kristalline Bruchfläche ist scharf, dunkler Untergrund, dramatisches Seitenlicht von links
Extremmakro einer gebrochenen weiĂźen Tablette: kristalline Bruchstruktur vor dunkelgrauem Hintergrund, Illustration mit AI erstellt.

Bayer (ISIN DE000BAY0017) stock is trading in the high-40 euro range as of August 12, 2026, with analysts now sharply divided on its upside after the company’s recent second quarter results and technical resistance around the mid-50 euro area, according to an analyst round-up reported on August 12, 2026.

Analyst targets diverge sharply on Bayer stock

According to a same-day analyst overview, Jefferies has reaffirmed a Hold rating on Bayer with a price target of 46 euros, only slightly above the current trading level as of August 12, 2026.

By contrast, other major banks cited in the same report have lifted their targets following Bayer’s second quarter release, with Goldman Sachs now pointing to 63.50 euros while UBS and DZ Bank cluster in the 60 to 63.50 euro range, creating a spread of more than 17.50 euros between the most cautious and most optimistic views.

Second quarter reaction and technical levels

In that analyst summary, Bayer shares are reported at 48.87 euros, marginally below the prior close of 49.12 euros as of August 12, 2026, leaving the stock about 9.26 percent under its 52-week high of 53.86 euros reached in early July 2026.

The same technical context highlights that Bayer shares remain comfortably above their 50-day moving average and have gained around one third since the start of 2026, suggesting the recent second quarter numbers and guidance have supported a steady recovery even as the stock trades below the mid-50 euro resistance area widely watched by chart specialists.

Go deeper

More on Bayer stock and its recent performance

Read additional coverage, financial metrics and regulatory news related to Bayer stock, including past earnings and sector developments.

Bayer’s pharmaceutical and crop science franchise

Bayer’s business model combines a large-scale pharmaceuticals operation, including cardiovascular and oncology treatments, with a global crop science segment that supplies seeds and crop protection products to farmers across North America, Europe and Asia.

Bayer stock trades in Europe with US investor interest

As of August 12, 2026, Bayer stock is quoted around 48.87 euros on its primary European exchange listing, staying below the 54 euro level often highlighted as a breakout threshold toward the 60 euro zone in the recent analyst commentary.

Bayer stock key data

  • Company: Bayer AG
  • ISIN: DE000BAY0017
  • Ticker: BAYN
  • Exchange: Xetra
  • Price (as of August 12, 2026): 48.87 euros
  • Sector / Industry: Health care - Pharmaceuticals and crop science
  • Index membership: DAX 40
  • Next earnings date: not yet officially scheduled

More on Bayer stock across social platforms

Disclaimer...

en | DE000BAY0017 | BAYER | boerse | 69943860 | bgmi